LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced new positive results demonstrating that its calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, BioVant™, may serve as an effective vaccine adjuvant for the development of a dose sparing vaccine against H5N1 avian flu, widely known as bird flu.